PLRX Share Price | Pliant Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Pliant Therapeutics, Inc.?

Market Cap: As of Jun 18, Pliant Therapeutics, Inc. has a market capitalization of 80.42 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, Pliant Therapeutics reported net sales of 0.00 million and a net profit of -219.51 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 304.08 million and total assets of 396.95 million.

Q: What does Pliant Therapeutics, Inc. do?

Overview:Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Profit: -56 Million (Quarterly Results - Mar 2025)Market cap: USD 80.42 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.07Return on Equity: -85.36%Price to Book: 0.31Contact Details:Address: 260 Littlefield Avenue, Suite 150, SOUTH SAN FRANCISCO CA: 94080Tel: 1 650 4816770Website: https://pliantrx.com/

Q: Is Pliant Therapeutics, Inc. overvalued or undervalued?

As of 6 May 2024, the valuation grade for Pliant Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its current price of $1.25, especially when compared to its peers. Key ratios include a Price to Book Value of 0.39 and an EV to EBITDA of 0.75, which suggest that the company's valuation metrics are not favorable compared to the industry.In comparison to its peers, Pliant Therapeutics, Inc. has a negative P/E ratio of -0.3663, while Aurinia Pharmaceuticals, Inc. holds a fair valuation with a P/E of 18.6866. Additionally, Disc Medicine, Inc. is also classified as does not qualify but has a significantly worse EV to EBITDA ratio of -7.7346. The company's recent performance has been poor, with a year-to-date return of -90.51%, starkly contrasting with the S&P 500's return of 2.44% in the same period, further reinforcing the view that Pliant is overvalued.

Q: Is Pliant Therapeutics, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Pliant Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish monthly, while Bollinger Bands show a similar pattern. The daily moving averages are bearish, and the Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish stance on the monthly chart. In terms of performance, Pliant Therapeutics has significantly underperformed against the S&P 500, with a year-to-date return of -88.69% compared to the S&P 500's 12.22%. This stark contrast highlights the ongoing challenges faced by the stock.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

726.68 k

Shareholding (Dec 2025)

FII

24.67%

Held by 96 FIIs

DII

37.5%

Held by 37 DIIs

Promoter

10.23%

How big is Pliant Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Pliant Therapeutics, Inc. has a market capitalization of 80.42 million, with net sales of 0.00 million and a net profit of -219.51 million for the latest four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 304.08 million and total assets of 396.95 million.

View full answer

What does Pliant Therapeutics, Inc. do?

22-Jun-2025

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for fibrosis. As of March 2025, it has a market cap of $80.42 million and reported a net profit loss of $56 million.

View full answer

Who are in the management team of Pliant Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Pliant Therapeutics, Inc. includes Dr. Bernard Coulie (CEO), Dr. Hoyoung Huh (Lead Independent Director), Mr. David Pyott, Dr. Suzanne Bruhn, Ms. Gayle Crowell, and Dr. John Curnutte, all serving as directors. They guide the company's strategic direction and operations.

View full answer

Is Pliant Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 6, 2024, Pliant Therapeutics, Inc. is considered overvalued at $1.25, with unfavorable valuation metrics and a year-to-date return of -90.51%, indicating a significant deterioration in its financial standing compared to peers.

View full answer

Is Pliant Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Pliant Therapeutics, Inc. has shifted to a mildly bearish trend, with mixed indicators showing a significant year-to-date underperformance of -88.69% compared to the S&P 500's 12.22%.

View full answer

Compare Pliant Therapeutics, Inc. with Similar Stocks

Relay Therapeutics, Inc.Deciphera Pharmaceuticals, Inc.Tango Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 81 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.05

Return on Equity

-87.67%

Price to Book

0.40

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-24 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-3.31%

6 Months

-23.03%

1 Year

-22.52%

2 Years

-91.96%

3 Years

-95.56%

4 Years

-84.46%

5 Years

-97.05%

Pliant Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-256.89%

EBIT to Interest (avg)

-105.54

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.40

EV to EBIT

0.69

EV to EBITDA

0.70

EV to Capital Employed

13.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1887.64%

ROE (Latest)

-87.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 31 Schemes (27.59%)

Foreign Institutions

Held by 96 Foreign Institutions (24.67%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.27% vs 39.26% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.70",
          "val2": "-27.70",
          "chgp": "25.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.80",
          "chgp": "-87.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.30",
          "val2": "-0.10",
          "chgp": "-4,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.60",
          "val2": "-26.30",
          "chgp": "10.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 29.01% vs -30.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-148.40",
          "val2": "-226.20",
          "chgp": "34.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "3.00",
          "chgp": "-13.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-149.30",
          "val2": "-210.30",
          "chgp": "29.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-20.70

-27.70

25.27%

Interest

0.10

0.80

-87.50%

Exceptional Items

-4.30

-0.10

-4,200.00%

Consolidate Net Profit

-23.60

-26.30

10.27%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 10.27% vs 39.26% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-148.40

-226.20

34.39%

Interest

2.60

3.00

-13.33%

Exceptional Items

-8.10

0.00

Consolidate Net Profit

-149.30

-210.30

29.01%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 29.01% vs -30.38% in Dec 2024

All Annual Results

Company CV

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-ß). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avß1. The Company’s second clinical-stage product candidate, PLN-1474, is a small-molecule, selective inhibitor of avß1 in development for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Company Coordinates

Company Details

260 Littlefield Avenue, Suite 150 , SOUTH SAN FRANCISCO CA : 94080

Tel: 1 650 48167701 650 4816770

https://pliantrx.com/

Registrar Details